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A novel enzyme immunoassay (EIA) for thyrotropin-releasing hormone (TRH) was developed which used 
N-(4-diazophenyl)maleimide (DPM) as a new heterobifunctional agent capable of cross-linking TRH to 
mercaptosuccinyl bovine serum albumin and to b-D-galactosidase. The resulting conjugates act as the 
immunogen producing anti-TRH serum in rabbits and the enzyme marker of TRH in the EIA, respectively. 
This EIA with a double-antibody technique was sensitive and reproducible in measuring TRH at concentra- 
tions as low as 50 pg per tube, and monospecific to the hormone showing no cross-reactivity with the hor- 
mone analogue L-pGlu-L-His-L-Pro and TRH constituents. Using this assay, the distribution of immuno- 
reactive TRH in the brain was determined easily in rats, The use of DPM should provide a valuable new 
method for developing EIA hitherto possible for other peptide hormones containing neither a free carboxy 
nor a free amino group, using imidazole, phenohc, and indole group(s) of the amino acid as a reaction site. 
Thyrotropin-releasing hormone Enzyme immunoassay N-(4-Diazophenyl)maleimide 
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1. INTRODUCTION 
Thyrotropin-releasing hormone (TRH) not only 
stimulates thyrotropin (TSH) release from the 
adenohypophysis but is also known to exert a 
variety of biological effects on prolactin secretion 
and the central nervous system. 
Among the various methods of detection of 
TRH, radioimmunoassay (RIA) has been most 
widely employed [l-6]. Recent studies have shown 
that enzyme immunoassay (EIA) overcomes 
drawbacks inherent in radiolabeling and may have 
a sensitivity comparable to RIA [7,8]. However, an 
EIA system for TRH has not previously been 
developed because of the lack of suitable methods 
for preparing a homogeneous conjugate of an en- 
zyme and TRH (which contains neither a free car- 
boxy1 nor a free amino group) that could be 
utilizable as a tracer. 
This report describes the use of N- 
(4-diazophenyl)maleimide (DPM) as a novel 
heterobifunctional agent cross-linking TRH 
through its imidazole group of histidine with thiol 
groups of mercaptosuccinylated bovine serum 
albumin and of P-D-galactosidase (EC 3.2.1.23). 
The resultant conjugates were used respectively as 
the immunogen to TRH and enzyme marker of 
TRH in developing EIA for TRH. 
2. MATERIALS AND METHODS 
2.1. Materials 
Synthetic TRH (L-pyroglu-L-His-L-ProNHz) 
and L-pyroglu-L-His-L-Pro were purchased from 
the Protein Research Foundation (Mino, Osaka) 
and Bioproducts (Brussels, Belgium), respectively. 
N-(4-Aminophenyl)maleimide (APM) was bought 
from Tokyo Kasei Kogyo (Tokyo) and P-D- 
galactosidase from Escherichia coli from 
Boehringer-Mannheim (Mannheim, FRG). 
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2.2. Preparation of immunogen to TRH 
The reactions involved in the preparative process 
used in this stsudy are shown in fig.1. 
2.3. Introduction of maleimide group into TRH 
DPM was prepared by dissolving 1.7 mg 
(9.2 pmol) APM in 175 ~1 of 1 N acetic acid and 
adding 1.3 mg (188~mol) of sodium nitrite in 
100 ,ul distilled water. The diazotization reaction 
was allowed to continue for 10 min at 4°C with in- 
termittent stirring. This solution was added to 
3.0 mg (8.27 pmol) TRH in 1.5 ml of a mixed solu 
tion of 1 M 2-amino-2-methyl-1,3-propanediol 
HCl buffer (pH 8.7) and tetrahydrofuran (1: 1, 
v/v) and the mixture incubated for 10 min at room 
temperature with stirring. Ethyl acetate (1.0 ml) 
was then added, and the mixture shaken vigorously 
followed by centrifugation at 1000 rpm. The 
aqueous layer (TRH-DPM) was used without fur- 
ther purification for preparing the conjugates with 
mercaptosuccinyl bovine serum albumin 
(MS - BSA) and with ,&galactosidase as the TRH 
immunogen and the tracer in the EIA, respectively. 
2.4. Immunogen to TRH 
TRH-DPM (-4.49 mg, 8.0 pmol) was incubated 
with MS. BSA containing 17 thiol groups per mol 
(5 mg) [7,8] in 1.0 ml of 0.1 M phosphate buffer 
(pH 7.0) containing 3 M urea at room temperature 
for 30 min with stirring. The conjugate (TRH- 
L-pGlu-L-He-L-ProNH2 
(TRH) 
+ 
N-(4-DIAZOPHENL) MALEIMIDE 
CONH, 
/3-D-GALACTOSIDASE TRH - DPM 
SH 
BSA- NHCOCH,CHCOOH 
c/3-GAL-SH) MS BSA 
N-N-m 
TRH-D-GAL 
N:N-[TRH 
TRH-DPM-MS BRA 
Fig.1. Scheme for preparation of the immunogen for TRH and of TRH-@-galactosidase conjugate. P-GAL, ,13- 
galactosidase. 
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DPM-MS - BSA) was purified by column 
chromatography on Sephadex G-100 (2.8 x 42 cm) 
with an eluent of 0.1 M phosphate buffer (pH 7.0) 
containing 3 M urea. 
2.5. Immunization 
Three female rabbits were given S.C. and i.m. in- 
jections of approx. 1 .O mg TRH-DPM-MS - BSA 
emulsified in Freund’s complete adjuvant. Booster 
injections were then given 4 times at biweekly in- 
tervals, using one-half the amount of the dose of 
the first immunization. 
2.6. Enzyme labeling of TRH (fig.l) 
TRH-DPM (-38.1 pg, 0.1 pmol) was incubated 
with fl-galactosidase (39pg, 0.07 nmol) [9] in 
1 .O ml of 0.1 M phosphate buffer (pH 6.0) at 
room temperature for 30 min. The reaction mix- 
ture was chromatographed on a column of 
Sephadex 6B (2 x 38 cm) with 20 mM phosphate 
buffer (pH 7.0) containing 0.1 M NaCl, 0.1% BSA 
and 0.1% NaN3 and with 3-ml fractions. Fractions 
of the main peak of the pure enzyme activity were 
chosen as a label in the EIA. 
2.7. Distribution of immunoreactive TRH in the 
brain 
Six Wistar rats weighing about 250-300 g were 
killed by decapitation. The brain was chilled quick- 
ly in cold 0.15 M NaCl and dissected into the 
cerebrum, thalamus, hypothalamus, brain stem 
and cerebellum as described by Oliver et al. [lo]. 
Each tissue was weighed and homogenized in 5 ml 
of 90% methanol (v/v) using a Polytron Model 
PT 10 (Brinkman Instruments, Westbury, NY). 
The homogenates were centrifuged at 0°C for 
15 min at 2500 rpm and the supernatants collected 
and evaporated to dryness in vacua. The residue 
was dissolved in 0.06 M sodium phosphate, pH 
7.4, containing 0.01 M EDTA, 0.1% BSA and 
0.1% NaN3 and measured by EIA. 
2.8. Measurement of fl-galactosidase activity and 
double-antibody EIA method 
These were performed essentially as described 
[7A111. 
3. RESULTS 
3.1. Antibody response 
TRH antisera were produced following the 
priming injection in each of the 3 rabbits immu- 
nized. Subsequent injections considerably in- 
creased the antiserum titers in the rabbits. The 
titers in the serum samples were measured in terms 
of enzyme activity of TRH-fl-galactosidase bound 
to solutions of antiserum obtained by the EIA. An- 
tiserum used in this study was obtained 2 weeks 
after the final injection, with the highest titer of 
the antibody approx. 20% (B/T) of the total en- 
zyme activity at final dilution 1: 3000. 
3.2. EIA of TRH 
A standard calibration curve of TRH measure- 
ment is shown in fig.2. The sensitivity of TRH 
assays, defined as the smallest amount 
distinguishable from zero at the 95% confidence 
level, is 50 pg/tube. TRH analogue (pGlu-His- 
Pro) and its constituents (pGlu-His, ProNH2, 
pGlu, His, and Pro) are tested for their ability to 
displace bound TRH-P-galactosidase conjugate, 
demonstrating that none compete significantly 
with the tracer against anti-TRH antibody in the 
EIA. 
The EIA measured the immunoreactive TRH in 
various brain tissues of male rats (table 1). The 
concentration was at its highest level in the 
hypothalamus (310 ng per g tissue), followed by 
55, 20, 5.5 and 2.6 rig/g in the thalamus, brain 
stem, cerebrum and cerebellum, respectively. 
x)-- lo-' 10" 10' IO' IO’ 10' 
Unlaklled drug hg/tube) 
Fig.2. Standard curve for TRH, and cross-reactivity of 
TRH analogue and TRH constituents with anti-TRH 
serum. The curves show the amount (Yo) of bound 
enzyme activity for various doses of TRH and TRH- 
related compounds (B) as a ratio of that bound using 
TRH-fl-galactosidase alone (B”). (0) TRH, (0) L-pGlu- 
L-His-L-Pro, (A) pGlu-His, (v) pGlu, (0) His, (0) 
ProNHz, (0) Pro. 
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Table 1 
Endogenous immunoreactive TRH contents in various brain 
tissues in rats 
Tissue Tissue wet wt TRH content TRH concen- 
(mg) (ng) tration 
(rig/g tissue) 
Hypothalamus 20.6 Y!I 2.0 6.39 + 0.42 310 + 25 
Thalamus 256.0 + 10.5 14.30 Y!I 2.05 55 -t 3.0 
Brain stem 212.8 f 12.0 4.35 f 0.45 20 k 1.3 
Cerebrum 1250.0 + 23.0 6.90 + 0.89 5.5 + 0.32 
Cerebellum 260.0 f 8.2 0.68 * 0.02 2.6 k 0.10 
Each value is the mean + SE obtained from 6 rats 
4. DISCUSSION 
Since 1972, a number of RIAs for the measure- 
ment of TRH have appeared [l-6]. The TRH im- 
munogen has been prepared by coupling TRH to 
carrier proteins by the use of the cross-linking 
agents bis-diazotized benzidine [l-3], p-diazoni- 
umphenylacetic acid [ 141 or 1,5-difluoro-2,4- 
dinitrobenzene [5], or directly coupling a TRH 
analogue, pGlu-His-Pro to the amino groups of a 
protein carrier with a carbodiimide [8]. These 
cross-linking agents, however, are unsuitable for 
preparing TRH-enzyme conjugate for use in 
developing EIA as a tracer, because these methods 
might produce as side-products complex polymers 
of enzyme and TRH. 
We used DPM (prepared by the diazotization 
reaction of the commercially available APM) as a 
heterobifunctional agent to conjugate TRH with 
proteins (MS - BSA or fl-galactosidase) by means of 
its 2 selective functional groups of diazo and 
maleimide acting on the imidazole of the histidyl 
moiety of TRH and the thiol groups of the pro- 
teins, respectively, in a two-step process. The first 
azo-coupling may occur at both or either of the 
points C-2 and C-5 in the imidazole group (see 
fig.1). The maleimide group of DPM was, 
however, unstable during the azo-coupling reac- 
tion with TRH at a weakly alkaline pH, and the 
conditions described in section 2 which preclude 
hydrolysis of the agent were chosen. Following the 
removal of unreacted APM by extraction with 
ethyl acetate, the maleimide group incorporated on 
a TRH molecule was then conjugated by thiolation 
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with the thiol groups of MS. BSA and p- 
galactosidase, and the resulting conjugates were 
used respectively as the immunogen producing 
anti-TRH serum and the enzyme marker of TRH 
in the EIA. The present method based on a two- 
step process is very mild and does not result in ex- 
tensive (intra- or intermolecular) self-coupling of 
TRH or proteins as occurs when other commonly 
used coupling agents are employed [l-6]. The 
TRH-DPM-MS * BSA thus prepared elicited the 
production of anti-TRH antibody in all.3 rabbits 
immunized, with the highest iter 2 weeks after the 
final booster injection. TRH-,&galactosidase as a 
tracer retained full enzyme activity of /3- 
galactosidase without loss during the conjugation 
reaction, and showed reasonable stability, remain- 
ing unchanged in its immunoreactive nzyme ac- 
tivity when stored at 4°C for several months. 
These reagents were used to develop an EIA for 
TRH which proved sensitive (with TRH at 
50 pg/tube, almost comparable sensitivity to RIA 
can be measured) and reproducible (10.8% varia- 
tion interassay as an average, not shown). This 
assay was quite specific to TRH and showed no 
cross-reactivity with TRH analogue and TRH con- 
stituents at a high concentration of 10 fig/tube. 
The utility of the EIA was demonstrated by its ap- 
plication to measure the brain distribution of im- 
munoreactive TRH in rats (table 1). The TRH 
levels in the tissues tested were very slightly higher 
and almost comparable to those reported by Oliver 
et al. [l l] by means of RIA for TRH. 
Based on the results of the present study, it is ex- 
pected that DPM could serve as a potent useful 
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heterobifunctional agent capable of cross-linking 
many other peptide hormones (even those which 
contain neither a free carboxyl nor a free amino 
group) to the thiol groups of proteins through im- 
idazole, phenolic, indole and a variety of other 
groups of the amino acid. The resulting conjugates 
may be used as the immunogen and the enzyme 
marker of the hormones in the EZIA. 
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